18F-FDG PET/CT在小细胞肺癌全程管理中的研究进展
Research Advances of 18F-FDG PET/CT in the Comprehensive Management of Small Cell Lung Cancer
DOI: 10.12677/acm.2026.1662349, PDF,   
作者: 刘 丽, 李万湖*：山东第一医科大学(山东省医学科学院)研究生院，山东 济南；山东第一医科大学附属肿瘤医院影像科，山东 济南
关键词: 小细胞肺癌；PET/CT；疗效评估；预后预测；Small Cell Lung Cancer； PET/CT； Efficacy Evaluation； Prognostic Prediction
摘要: 小细胞肺癌(SCLC)属于肺神经内分泌肿瘤中最常见的亚型，约占所有原发性肺恶性肿瘤的15%~20%，具有侵袭性强、早期易转移的生物学特性，其诊疗管理高度依赖精准的影像学评估。18氟–脱氧葡萄糖正电子发射计算机断层显像(18F-FDG PET/CT)作为一种融合功能代谢与解剖结构的分子影像技术，凭借其对肿瘤代谢活性的高敏感性，尤其对隐匿性远处转移的检出显著优于传统影像学手段，已成为SCLC诊疗中的重要影像学工具，在SCLC的全程管理中扮演着重要的角色。本文旨在系统阐述18F-FDG PET/CT在SCLC诊疗各阶段的应用价值与研究进展。
Abstract: Small cell lung cancer (SCLC) is the most common subtype of pulmonary neuroendocrine tumors, accounting for approximately 15%~20% of all primary malignant lung tumors. Characterized by strong invasiveness and an early tendency for metastasis, the diagnosis and management of SCLC rely heavily on precise imaging evaluation. As a molecular imaging modality integrating functional metabolic imaging with anatomical structural imaging, 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) has become an important imaging tool in the diagnosis and treatment of SCLC due to its high sensitivity for detecting tumor metabolic activity, particularly its superior ability to identify occult distant metastases compared with conventional imaging techniques. Consequently, 18F-FDG PET/CT plays a crucial role throughout the entire management of SCLC. This review aims to systematically summarize the clinical applications and recent research advances of 18F-FDG PET/CT at different stages of SCLC management.
文章引用：刘丽, 李万湖. 18F-FDG PET/CT在小细胞肺癌全程管理中的研究进展[J]. 临床医学进展, 2026, 16(6): 1381-1389. https://doi.org/10.12677/acm.2026.1662349

参考文献

[1] 郑荣寿, 陈茹, 韩冰峰, 等. 2022年中国恶性肿瘤流行情况分析[J]. 中华肿瘤杂志, 2024, 46(3): 221-231.
[2] 张希, 杨雷, 刘硕, 等. 2022年全球恶性肿瘤统计报告解读[J]. 中华肿瘤杂志, 2024, 46(7): 710-721.
[3] Kim, S.Y., Park, H.S. and Chiang, A.C. (2025) Small Cell Lung Cancer: A Review. JAMA, 333, 1906-1917. [Google Scholar] [CrossRef] [PubMed]
[4] Wang, W.Z., Shulman, A., Amann, J.M., Carbone, D.P. and Tsichlis, P.N. (2022) Small Cell Lung Cancer: Subtypes and Therapeutic Implications. Seminars in Cancer Biology, 86, 543-554. [Google Scholar] [CrossRef] [PubMed]
[5] Du, J., Zhang, Q., Tian, L., Chen, Y., Tian, Y., Dempke, W.C.M., et al. (2024) Prognostic Roles of Hematological Indicators in Programmed Cell Death Protein 1/Programmed Cell Death Ligand 1 Inhibitors for Small-Cell Lung Cancer: A Retrospective Cohort Study. Journal of Thoracic Disease, 16, 8669-8683. [Google Scholar] [CrossRef] [PubMed]
[6] Le Pechoux, C., Faivre-Finn, C., Ramella, S., McDonald, F., Manapov, F., Putora, P.M., et al. (2020) ESTRO ACROP Guidelines for Target Volume Definition in the Thoracic Radiation Treatment of Small Cell Lung Cancer. Radiotherapy and Oncology, 152, 89-95. [Google Scholar] [CrossRef] [PubMed]
[7] Raso, M.G., Bota-Rabassedas, N. and Wistuba, I.I. (2021) Pathology and Classification of SCLC. Cancers, 13, Article 820. [Google Scholar] [CrossRef] [PubMed]
[8] Tian, Y., Li, Q., Yang, Z., Zhang, S., Xu, J., Wang, Z., et al. (2022) Single-Cell Transcriptomic Profiling Reveals the Tumor Heterogeneity of Small-Cell Lung Cancer. Signal Transduction and Targeted Therapy, 7, Article No. 346. [Google Scholar] [CrossRef] [PubMed]
[9] Dingemans, A.C., Früh, M., Ardizzoni, A., Besse, B., Faivre-Finn, C., Hendriks, L.E., et al. (2021) Small-Cell Lung Cancer: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up. Annals of Oncology, 32, 839-853. [Google Scholar] [CrossRef] [PubMed]
[10] 中华医学会肿瘤学分会, 中华医学会杂志社. 中华医学会肺癌临床诊疗指南(2022版) [J]. 中华医学杂志, 2022, 102(23): 1706-1740.
[11] Yuan, C., Zhang, M., Huang, X., Xie, W., Lin, X., Zhao, W., et al. (2021) Diffuse Large B‐Cell Lymphoma Segmentation in PET‐CT Images via Hybrid Learning for Feature Fusion. Medical Physics, 48, 3665-3678. [Google Scholar] [CrossRef] [PubMed]
[12] Quartuccio, N., Evangelista, L., Alongi, P., Caobelli, F., Altini, C., Cistaro, A., et al. (2019) Prognostic and Diagnostic Value of [18F]FDG-PET/CT in Restaging Patients with Small Cell Lung Carcinoma: An Italian Multicenter Study. Nuclear Medicine Communications, 40, 808-814. [Google Scholar] [CrossRef] [PubMed]
[13] Xu, P. and Wang, Y. (2020) Application of 18F-FDG PET/CT in Evaluation of Curative Effect and Prognosis for Small Cell Lung Cancer. Journal of Central South University. Medical sciences, 45, 1255-1260. (In Chinese)
[14] Nicholson, A.G., Chansky, K., Crowley, J., Beyruti, R., Kubota, K., Turrisi, A., et al. (2016) The International Association for the Study of Lung Cancer Lung Cancer Staging Project: Proposals for the Revision of the Clinical and Pathologic Staging of Small Cell Lung Cancer in the Forthcoming Eighth Edition of the TNM Classification for Lung Cancer. Journal of Thoracic Oncology, 11, 300-311. [Google Scholar] [CrossRef] [PubMed]
[15] 邵俊伟, 潘学兵, 袁志鹏, 等. 初诊小细胞肺癌(SCLC)分期及预后评价中18F-FDG PET/CT的价值[J]. 中国CT和MRI杂志, 2022, 20(8): 71-73.
[16] Manoharan, P., Salem, A., Mistry, H., Gornall, M., Harden, S., Julyan, P., et al. (2019) 18F-Fludeoxyglucose PET/CT in SCLC: Analysis of the CONVERT Randomized Controlled Trial. Journal of Thoracic Oncology, 14, 1296-1305. [Google Scholar] [CrossRef] [PubMed]
[17] Nestle, U., Schimek-Jasch, T., Kremp, S., Schaefer-Schuler, A., Mix, M., Küsters, A., et al. (2020) Imaging-Based Target Volume Reduction in Chemoradiotherapy for Locally Advanced Non-Small-Cell Lung Cancer (Pet-Plan): A Multicentre, Open-Label, Randomised, Controlled Trial. The Lancet Oncology, 21, 581-592. [Google Scholar] [CrossRef] [PubMed]
[18] Ohno, Y., Yoshikawa, T., Takenaka, D., Koyama, H., Aoyagi, K., Yui, M., et al. (2022) Small Cell Lung Cancer Staging: Prospective Comparison of Conventional Staging Tests, FDG PET/CT, Whole-Body MRI, and Coregistered FDG PET/MRI. American Journal of Roentgenology, 218, 899-908. [Google Scholar] [CrossRef] [PubMed]
[19] 董书含, 殷小平. 小细胞肺癌的影像新进展[J]. 实用放射学杂志, 2024, 40(12): 2087-2090.
[20] Pencharz, D., Matei, N., Jeon, J., Myerson, J. and Marchbank, N.D. (2021) Identification of Specific SUVmax Ratios Enhances Diagnostic Accuracy for Staging of Intrathoracic Nodes in Lung Cancer. Nuclear Medicine Communications, 42, 1130-1134. [Google Scholar] [CrossRef] [PubMed]
[21] Kishida, Y., Seki, S., Yoshikawa, T., Itoh, T., Maniwa, Y., Nishimura, Y., et al. (2018) Performance Comparison between 18F-FDG PET/CT Plus Brain MRI and Conventional Staging Plus Brain MRI in Staging of Small Cell Lung Carcinoma. American Journal of Roentgenology, 211, 185-192. [Google Scholar] [CrossRef] [PubMed]
[22] Yu, B., Zhu, X., Liang, Z., Sun, Y., Zhao, W. and Chen, K. (2018) Clinical Usefulness of 18F-FDG PET/CT for the Detection of Distant Metastases in Patients with Non-Small Cell Lung Cancer at Initial Staging: A Meta-Analysis. Cancer Management and Research, 10, 1859-1864. [Google Scholar] [CrossRef] [PubMed]
[23] Martucci, F., Pascale, M., Valli, M.C., Pesce, G.A., Froesch, P., Giovanella, L., et al. (2020) Impact of 18F-FDG PET/CT in Staging Patients with Small Cell Lung Cancer: A Systematic Review and Meta-Analysis. Frontiers in Medicine, 6, Article 336. [Google Scholar] [CrossRef] [PubMed]
[24] Ganti, A.K.P., Loo, B.W., Bassetti, M., Blakely, C., Chiang, A., D’Amico, T.A., et al. (2021) Small Cell Lung Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network, 19, 1441-1464. [Google Scholar] [CrossRef] [PubMed]
[25] Eisenhauer, E.A., Therasse, P., Bogaerts, J., Schwartz, L.H., Sargent, D., Ford, R., et al. (2009) New Response Evaluation Criteria in Solid Tumours: Revised RECIST Guideline (Version 1.1). European Journal of Cancer, 45, 228-247. [Google Scholar] [CrossRef] [PubMed]
[26] Ahmed, F.S., Dercle, L., Goldmacher, G.V., Yang, H., Connors, D., Tang, Y., et al. (2021) Comparing RECIST 1.1 and Irecist in Advanced Melanoma Patients Treated with Pembrolizumab in a Phase II Clinical Trial. European Radiology, 31, 1853-1862. [Google Scholar] [CrossRef] [PubMed]
[27] 许珮珮, 王云华. 18F-FDG PET/CT在小细胞肺癌疗效与预后评价中的应用[J]. 中南大学学报(医学版), 2020, 45(10): 1255-1260.
[28] Wahl, R.L., Jacene, H., Kasamon, Y. and Lodge, M.A. (2009) From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors. Journal of Nuclear Medicine, 50, 122S-150S. [Google Scholar] [CrossRef] [PubMed]
[29] Young, H., Baum, R., Cremerius, U., Herholz, K., Hoekstra, O., Lammertsma, A.A., et al. (1999) Measurement of Clinical and Subclinical Tumour Response Using [18F]-Fluorodeoxyglucose and Positron Emission Tomography: Review and 1999 EORTC Recommendations. European Journal of Cancer, 35, 1773-1782. [Google Scholar] [CrossRef] [PubMed]
[30] Kaira, K., Higuchi, T., Naruse, I., Arisaka, Y., Tokue, A., Altan, B., et al. (2018) Metabolic Activity by 18F-FDG-PET/CT Is Predictive of Early Response after Nivolumab in Previously Treated NSCLC. European Journal of Nuclear Medicine and Molecular Imaging, 45, 56-66. [Google Scholar] [CrossRef] [PubMed]
[31] Yu, X., Zhu, Y., Wang, J., Song, X., Zhu, L., Men, X., et al. (2017) Pretreatment Metabolic Parameters Measured by 18F-FDG-PET to Predict the Outcome of First-Line Chemotherapy in Extensive-Stage Small-Cell Lung Cancer. Nuclear Medicine Communications, 38, 193-200. [Google Scholar] [CrossRef] [PubMed]
[32] Umeda, Y., Morikawa, M., Anzai, M., Ameshima, S., Kadowaki, M., Waseda, Y., et al. (2020) Predictive Value of Integrated 18F-FDG PET/MRI in the Early Response to Nivolumab in Patients with Previously Treated Non-Small Cell Lung Cancer. Journal for ImmunoTherapy of Cancer, 8, e000349. [Google Scholar] [CrossRef] [PubMed]
[33] Cheng, Y., Jiang, Z., Chen, X., Lu, K., Liu, Z. and Shao, D. (2025) Prognostic Value of 18F-FDG PET/CT Metabolic Parameters in Resectable Non-Small Cell Lung Cancer Treated with Neoadjuvant Immunotherapy Plus Chemotherapy. Clinical Nuclear Medicine, 50, e344-e351. [Google Scholar] [CrossRef] [PubMed]
[34] Lin, X., Xiao, Z., Hu, Y., Zhang, X. and Fan, W. (2020) Combining 18F‐FDG PET/CT and Serum Lactate Dehydrogenase for Prognostic Evaluation of Small Cell Lung Cancer. Frontiers in Pharmacology, 11, Article 592768. [Google Scholar] [CrossRef] [PubMed]
[35] Choi, E.K., Park, M., Im, J.J., Chung, Y. and Oh, J.K. (2020) Prognostic Value of 18F-FDG PET/CT Metabolic Parameters in Small Cell Lung Cancer. Journal of International Medical Research, 48, 1-10. [Google Scholar] [CrossRef] [PubMed]
[36] Kim, H., Yoo, I.R., Boo, S.H., Park, H.L., O, J.H. and Kim, S.H. (2018) Prognostic Value of Pre-and Post-Treatment FDG PET/CT Parameters in Small Cell Lung Cancer Patients. Nuclear Medicine and Molecular Imaging, 52, 31-38. [Google Scholar] [CrossRef] [PubMed]
[37] Araz, M., Soydal, C., Özkan, E., Sen, E., Nak, D., Kucuk, O.N., et al. (2022) Prognostic Value of Metabolic Parameters on Baseline 18F-FDG PET/CT in Small Cell Lung Cancer. The Quarterly Journal of Nuclear Medicine and Molecular Imaging, 66, 61-66. [Google Scholar] [CrossRef] [PubMed]
[38] Christensen, T.N., Andersen, P.K., Langer, S.W. and Fischer, B.M.B. (2021) Prognostic Value of 18F-FDG-PET Parameters in Patients with Small Cell Lung Cancer: A Meta-Analysis and Review of Current Literature. Diagnostics, 11, Article 174. [Google Scholar] [CrossRef] [PubMed]
[39] 陈香, 乔文礼, 宋建华, 等. 18F-FDG PET/CT对初诊弥漫大B细胞淋巴瘤骨髓浸润的诊断及预后评估价值[J]. 中国实验血液学杂志, 2023, 31(4): 1044-1049.
[40] 翟威豪, 何薇. 18F-FDG PET/CT参数SUVpeak、全身代谢肿瘤体积和总糖酵解值对弥对弥漫大B细胞淋巴瘤患者预后的预测价值[J]. 分子影像学杂志, 2021, 44(5): 787-791.
[41] 冯昭, 王洋, 范志刚. 基于18F-FDG PET/CT对广泛期小细胞肺癌预后预测模型的构建[J]. 河北医学, 2024, 30(7): 1210-1215.
[42] Liu, C., Lin, L., Tsai, C., Huang, T., Wu, Y. and Liu, C. (2026) Baseline ¹8F-FDG PET/CT Radiomics Predict Early Progression and Survival in Small Cell Lung Cancer. BMC Cancer, 26, Article No. 222. [Google Scholar] [CrossRef] 
[43] 孟鑫, 郭宏, 王丽, 等. 18氟-氟代脱氧葡萄糖正电子发射断层显像/X线计算机体层成像仪代谢指标对局限期与广泛期小细胞肺癌预后的预测研究[J]. 中国全科医学, 2019, 22(2): 173-179.
[44] Hashimoto, K., Kaira, K., Imai, H., Miura, Y., Shiono, A., Mouri, A., et al. (2024) Metabolic Tumor Volume as Significant Predictor for Chemotherapy Containing PD-L1 Blocker in Extensive Stage Small Cell Lung Cancer. Anticancer Research, 44, 1541-1551. [Google Scholar] [CrossRef] [PubMed]
[45] Chang, H., Lee, S.J., Lim, J., Lee, J.S., Kim, Y.J. and Lee, W.W. (2019) Prognostic Significance of Metabolic Parameters Measured by 18F-FDG PET/CT in Limited-Stage Small-Cell Lung Carcinoma. Journal of Cancer Research and Clinical Oncology, 145, 1361-1367. [Google Scholar] [CrossRef] [PubMed]
[46] Brose, A., Miederer, I., König, J., Gkika, E., Sahlmann, J., Schimek-Jasch, T., et al. (2024) Prognostic Value of Metabolic Tumor Volume on [18F]FDG PET/CT in Addition to the TNM Classification System of Locally Advanced Non-Small Cell Lung Cancer. Cancer Imaging, 24, Article No. 171. [Google Scholar] [CrossRef] [PubMed]
[47] Lapa, P., Oliveiros, B., Marques, M., Isidoro, J., Alves, F.C., Costa, J.M.N., et al. (2017) Metabolic Tumor Burden Quantified on [18F]FDG PET/CT Improves TNM Staging of Lung Cancer Patients. European Journal of Nuclear Medicine and Molecular Imaging, 44, 2169-2178. [Google Scholar] [CrossRef] [PubMed]
[48] Kersting, D., Sandach, P., Sraieb, M., Wiesweg, M., Metzenmacher, M., Darwiche, K., et al. (2023) 68Ga-SSO-120 PET for Initial Staging of Small Cell Lung Cancer Patients: A Single-Center Retrospective Study. Journal of Nuclear Medicine, 64, 1540-1549. [Google Scholar] [CrossRef] [PubMed]
[49] Evangelista, L., Fiz, F., Laudicella, R., Bianconi, F., Castello, A., Guglielmo, P., et al. (2023) PET Radiomics and Response to Immunotherapy in Lung Cancer: A Systematic Review of the Literature. Cancers, 15, Article 3258. [Google Scholar] [CrossRef] [PubMed]
[50] Nie, Y., Schalper, K.A. and Chiang, A. (2024) Mechanisms of Immunotherapy Resistance in Small Cell Lung Cancer. Cancer Drug Resistance, 7, Article 55. [Google Scholar] [CrossRef] [PubMed]

为你推荐